Building From Experience
At Exo-Harvest, our team comes from the world of biologics. We're scientists and engineers who’ve lived the day-to-day challenges of scaling adherent cell cultures for exosomes, gene therapy, and cell therapy. We've been through it, we understand, so we built the solution we wished we had.
Our mission is to transform cell-derived product manufacturing by tackling the real bottlenecks: yield, consistency, and scalability. The result is a platform that delivers efficient, cost-effective solutions to support biotech teams from discovery to production.
Our team.
Meet the biotech and engineering experts developing our solutions.
Dr. Jean-Paul Prieels brings decades of expertise in vaccine and biologics development. Formerly SVP of R&D at GlaxoSmithKline Biologicals, he led global vaccine research initiatives from early discovery through product development. Since 2011, he has advised and invested in multiple biotech ventures across vaccines, oncology, and cell therapy. He co-founded MaSTherCell and convEyXO, where he continues to shape the future of biotech innovation.
Biotech R&D Strategist | Vaccine & Cell Therapy Innovator
.avif)
David Sergeant is the founder of Ipratech, a specialist in software and automation for cell and gene therapy manufacturing. With a background in industrial systems and IT architecture, he has developed platforms that streamline bioprocess monitoring, data integration, and compliance. His work enables smarter, more scalable biomanufacturing to power next-gen therapeutic production.
Bioprocess Automation Expert | Founder, Ipratech
Frédéric Tonglet combines 25+ years of experience in finance, governance, and biotech commercialization. Formerly CFO of MaSTherCell and Governance Officer at Orgenesis, he played key roles in high-value transactions, investor relations, and a successful NASDAQ up-listing. Now CEO of convEyXO, he helps biotech ventures navigate growth, strategy, and operational scale-up.
Biotech Business Architect | Financial Strategy & Growth Leader
Connect with Our Experts
We welcome inquiries and collaboration opportunities to advance cell therapy, extracellular vesicle, and viral vector manufacturing together.